{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T11:03:09Z","timestamp":1771844589347,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"National Institute for Health Research Health Technology Assessment Programme","award":["09\/51\/01"],"award-info":[{"award-number":["09\/51\/01"]}]},{"name":"Arthritis Research United Kingdom","award":["19612"],"award-info":[{"award-number":["19612"]}]},{"DOI":"10.13039\/100012141","name":"University Hospitals Bristol NHS Foundation Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012141","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","aaojournal.org","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.ophtha.2018.09.043","type":"journal-article","created":{"date-parts":[[2018,10,16]],"date-time":"2018-10-16T00:02:54Z","timestamp":1539648174000},"page":"415-424","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Cost-Effectiveness Analysis of Adalimumab for the Treatment of Uveitis Associated with Juvenile Idiopathic Arthritis"],"prefix":"10.1016","volume":"126","author":[{"given":"Dyfrig A.","family":"Hughes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanna","family":"Culeddu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catrin O.","family":"Plumpton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eifiona","family":"Wood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew D.","family":"Dick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley P.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1312-8911","authenticated-orcid":false,"given":"Andrew","family":"McKay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula R.","family":"Williamson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandrine","family":"Compeyrot Lacassagne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1050-5777","authenticated-orcid":false,"given":"Ben","family":"Hardwick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Hickey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3132-2665","authenticated-orcid":false,"given":"Patricia","family":"Woo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5400-9911","authenticated-orcid":false,"given":"Michael W.","family":"Beresford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Athimalaipet V.","family":"Ramanan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ophtha.2018.09.043_bib1","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/art.22381","article-title":"Prevalence, risk factors, and outcome of uveitis in juvenile idiopathic arthritis: a long-term followup study","volume":"56","author":"Saurenmann","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.ophtha.2018.09.043_bib2","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1016\/S0161-6420(01)00773-4","article-title":"Occurrence of uveitis in recently diagnosed juvenile chronic arthritis: a prospective study","volume":"108","author":"Kotaniemi","year":"2001","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.ophtha.2018.09.043_bib3","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2165\/00148581-200911040-00002","article-title":"Non-infectious pediatric uveitis: an update on immunomodulatory management","volume":"11","author":"Sharma","year":"2009","journal-title":"Paediatr Drugs"},{"issue":"2","key":"10.1016\/j.ophtha.2018.09.043_bib4","first-page":"362","article-title":"Methotrexate is an effective treatment for chronic uveitis associated with juvenile idiopathic arthritis","volume":"32","author":"Foeldvari","year":"2005","journal-title":"J\u00a0Rheumatol"},{"issue":"2","key":"10.1016\/j.ophtha.2018.09.043_bib5","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0022-3476(98)70232-X","article-title":"Methotrexate for resistant chronic uveitis in children with juvenile rheumatoid arthritis","volume":"133","author":"Weiss","year":"1998","journal-title":"J\u00a0Pediatr"},{"issue":"5","key":"10.1016\/j.ophtha.2018.09.043_bib6","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1080\/09273940590951061","article-title":"Outcomes of treatment with immunomodulatory therapy in patients with corticosteroid-resistant juvenile idiopathic arthritis-associated chronic iridocyclitis","volume":"13","author":"Yu","year":"2005","journal-title":"Ocul Immunol Inflamm"},{"issue":"8","key":"10.1016\/j.ophtha.2018.09.043_bib7","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa0706290","article-title":"Adalimumab with or without methotrexate in juvenile rheumatoid arthritis","volume":"359","author":"Lovell","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ophtha.2018.09.043_bib8","article-title":"Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis","year":"2015","journal-title":"NICE Technology appraisal guidance 373"},{"issue":"17","key":"10.1016\/j.ophtha.2018.09.043_bib9","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJMoa1614160","article-title":"Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis","volume":"376","author":"Ramanan","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ophtha.2018.09.043_bib10","unstructured":"Joint Formulary Committee. British National Formulary. (online) London: BMJ Group and Pharmaceutical Press; Available at: http:\/\/www.medicinescomplete.com; Accessed on 18\/01\/2017."},{"issue":"68","key":"10.1016\/j.ophtha.2018.09.043_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta21680","article-title":"A\u00a0systematic review and economic evaluation of adalimumab and dexamethasone for treating non-infectious intermediate uveitis, posterior uveitis or panuveitis in adults","volume":"21","author":"Squires","year":"2017","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.ophtha.2018.09.043_bib12","unstructured":"Specialised Commissioning Team NHS England. Interim clinical commissioning policy: adalimumab for children with severe refractory uveitis. D12X02. 2015. Available at: https:\/\/www.bnssgformulary.nhs.uk\/includes\/documents\/d12x02-paediatric-uveitis-anti-tnf.pdf; Accessed 30\/01\/2018."},{"key":"10.1016\/j.ophtha.2018.09.043_bib13","unstructured":"All Wales Medicines Advisory Group. Final appraisal recommendation. Advice no: 2717. Adalimumab (Humira\u00ae) 40 mg solution for injection (pre-filled pen, pre-filled syringe and vial). 2017. Available at: http:\/\/www.awmsg.org\/awmsgonline\/app\/appraisalinfo\/3035; Accessed 30\/01\/2018."},{"key":"10.1016\/j.ophtha.2018.09.043_bib14","unstructured":"Scottish Medicines Consortium. Statement of advice: adalimumab 40mg\/0.4mL pre-filled syringe and pre-filled pen \/ adalimumab 40mg\/0.4mL 40mg\/0.8mL vial for paediatric use (Humira\u00ae) SMC No 1305\/18. 2017. Available at: https:\/\/www.scottishmedicines.org.uk\/media\/3090\/adalimumab_humira_non_sub_final_dec_2017_for_website.pdf; Accessed 30\/01\/2018."},{"key":"10.1016\/j.ophtha.2018.09.043_bib15","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1745-6215-15-14","article-title":"A\u00a0randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial)","volume":"15","author":"Ramanan","year":"2014","journal-title":"Trials"},{"issue":"1","key":"10.1016\/j.ophtha.2018.09.043_bib16","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12969-018-0266-5","article-title":"Outcomes of non-infectious paediatric uveitis in the era of biologic therapy","volume":"16","author":"Cann","year":"2018","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.ophtha.2018.09.043_bib17","doi-asserted-by":"crossref","first-page":"f1049","DOI":"10.1136\/bmj.f1049","article-title":"Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement","volume":"346","author":"Husereau","year":"2013","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.ophtha.2018.09.043_bib18","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/00005650-200202000-00006","article-title":"Multiattribute and single-attribute utility functions for the health utilities index mark 3 system","volume":"40","author":"Feeny","year":"2002","journal-title":"Med Care"},{"issue":"8","key":"10.1016\/j.ophtha.2018.09.043_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0135672","article-title":"Measuring health utilities in children and adolescents: a systematic review of the literature","volume":"10","author":"Thorrington","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ophtha.2018.09.043_bib20","unstructured":"National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013. Process and methods [PMG9]. 2013. Available at: https:\/\/www.nice.org.uk\/process\/pmg9\/chapter\/foreword; Accessed 18\/01\/2017."},{"issue":"8","key":"10.1016\/j.ophtha.2018.09.043_bib21","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.jval.2011.07.011","article-title":"EQ-5D for the assessment of health-related quality of life and resource allocation in children: a systematic methodological review","volume":"14","author":"Noyes","year":"2011","journal-title":"Value Health"},{"issue":"9","key":"10.1016\/j.ophtha.2018.09.043_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta18090","article-title":"Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: a systematic review, statistical modelling and survey","volume":"18","author":"Longworth","year":"2014","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.ophtha.2018.09.043_bib23","unstructured":"NHS Business Services Authority. Prescription Cost Analysis (PCA) data. October 2016. Available at: https:\/\/www.nhsbsa.nhs.uk\/prescription-data\/dispensing-data\/prescription-cost-analysis-pca-data foreword; Accessed 18\/01\/2017."},{"key":"10.1016\/j.ophtha.2018.09.043_bib24","unstructured":"NHS National Tariff Payment System 2016\/17. Available at: https:\/\/www.gov.uk\/government\/publications\/nhs-national-tariff-payment-system-201617; Accessed 31\/10\/2016."},{"key":"10.1016\/j.ophtha.2018.09.043_bib25","unstructured":"Department of Health. NHS England and NHS Improvement. NHS Reference Costs 2015-2016. Department of Health and Social Care. 2016. Available at: https:\/\/www.gov.uk\/government\/publications\/nhs-reference-costs-2015-to-2016; Accessed 03\/10\/2017."},{"key":"10.1016\/j.ophtha.2018.09.043_bib26","series-title":"Unit Costs of Health and Social Care 2015","author":"Curtis","year":"2015"},{"issue":"suppl 1","key":"10.1016\/j.ophtha.2018.09.043_bib27","first-page":"i153","article-title":"Standardized mortality rates are increased in patients with severe juvenile idiopathic arthritis","volume":"54","author":"Davies","year":"2015","journal-title":"Rheumatology"},{"key":"10.1016\/j.ophtha.2018.09.043_bib28","author":"Shkolnikov"},{"issue":"4","key":"10.1016\/j.ophtha.2018.09.043_bib29","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/sim.4067","article-title":"Multiple imputation using chained equations: issues and guidance for practice","volume":"30","author":"White","year":"2011","journal-title":"Stat Med"},{"key":"10.1016\/j.ophtha.2018.09.043_bib30","doi-asserted-by":"crossref","first-page":"c2073","DOI":"10.1136\/bmj.c2073","article-title":"An IV for the RCT: using instrumental variables to adjust for treatment contamination in randomised controlled trials","volume":"340","author":"Sussman","year":"2010","journal-title":"BMJ"},{"issue":"34","key":"10.1016\/j.ophtha.2018.09.043_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta20340","article-title":"The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation","volume":"20","author":"Shepherd","year":"2016","journal-title":"Health Technol Assess"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642018311461?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642018311461?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T13:37:36Z","timestamp":1565271456000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642018311461"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S0161642018311461"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2018.09.043","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness Analysis of Adalimumab for the Treatment of Uveitis Associated with Juvenile Idiopathic Arthritis","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2018.09.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}